Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

Launched by THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY · Aug 7, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent.
• • 2. patients must have confirmation of APL by WHO criteria, previously untreated, and eligible for treatment with intensive chemotherapy as defined by the following: Cardiac history of congestive heart failure requiring treatment or ejection fraction ≤ 50% or chronic stable angina. Diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65% or forced expiratory volume during the first second (FEV1) ≤ 65%. Creatinine clearance \< 45 mL/min. Moderate hepatic impairment with total bilirubin \> 1.5 × ULN. Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy.
• Exclusion Criteria:
• • 1. Patient is ineligible for treatment with intensive chemotherapy
• • 2. Patient with active infection not controlled, active bleeding from vital organs
• • 3. Patient with history of clinically significant drug or alcohol abuse that would adversely affect evaluation in this study